The concept of AR as a breast cancer oncogene, and the availability of effective AR-targeting agents used to treat prostate cancer, has elicited clinical trials assessing the efficacy of AR antagonists and androgen biosynthesis inhibitors in preventing disease progression in women with advanced, metastatic breast cancer. Here, AR is linked to Familial prostate cancer.